Cost burden of chemotherapy for Indonesian healthcare insurance and social security/Jaminan Kesehatan Nasional (JKN) patients with non-Hodgkin lymphoma.

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2024-06-11 DOI:10.1177/10781552241261250

Yulistiani Yulistiani, Erfan Abdissalam, Abdul Rahem, Nur Fauzi Hamidi, Febriansyah Nur Utomo

{"title":"Cost burden of chemotherapy for Indonesian healthcare insurance and social security/Jaminan Kesehatan Nasional (JKN) patients with non-Hodgkin lymphoma.","authors":"Yulistiani Yulistiani, Erfan Abdissalam, Abdul Rahem, Nur Fauzi Hamidi, Febriansyah Nur Utomo","doi":"10.1177/10781552241261250","DOIUrl":null,"url":null,"abstract":"Background: Cancer is among the leading causes of death globally, posing a significant economic burden on the healthcare sector. Among other types of cancer in Indonesia, non-Hodgkin lymphoma (NHL) ranks fifth in terms of prevalence. Chemotherapy for NHL patients is funded by a national health insurance scheme through the National Healthcare Insurance and Social Security/Jaminan Kesehatan Nasional (JKN).Objective: This study aimed to analyze cost burden of chemotherapy for JKN patients with NHL.Data source: A retrospective cross-sectional observational study was conducted among NHL patients receiving chemotherapy at a hospital in East Java, Indonesia in 2021. Data were collected from medical record documents and a total of 44 patient visits were recorded in this study.Data summary: The result showed that patient visits were dominated by females (55%), a significant proportion were aged 31 to 40 years (32%), and the majority were JKN participants in the Contribution Assistance Recipients/Penerima Bantuan Iuran (PBI) category (64%). The most chemotherapy regimen given was R-CHOP (68%) and the mean total cost for NHL patients was Indonesian Rupiah (IDR) 5,178,146. The highest mean cost burden was on chemotherapy drugs with a value of IDR 6,333,315. Based on the regimen, the highest cost burden was R-CHOP-Bleo with a mean cost of IDR 8,764,091.Conclusion: Based on the results, the highest cost burden for chemotherapy among JKN patients with NHL in Indonesia was attributed to R-CHOP-Bleo regimen with a mean of IDR 8,764,091.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241261250","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer is among the leading causes of death globally, posing a significant economic burden on the healthcare sector. Among other types of cancer in Indonesia, non-Hodgkin lymphoma (NHL) ranks fifth in terms of prevalence. Chemotherapy for NHL patients is funded by a national health insurance scheme through the National Healthcare Insurance and Social Security/Jaminan Kesehatan Nasional (JKN).

Objective: This study aimed to analyze cost burden of chemotherapy for JKN patients with NHL.

Data source: A retrospective cross-sectional observational study was conducted among NHL patients receiving chemotherapy at a hospital in East Java, Indonesia in 2021. Data were collected from medical record documents and a total of 44 patient visits were recorded in this study.

Data summary: The result showed that patient visits were dominated by females (55%), a significant proportion were aged 31 to 40 years (32%), and the majority were JKN participants in the Contribution Assistance Recipients/Penerima Bantuan Iuran (PBI) category (64%). The most chemotherapy regimen given was R-CHOP (68%) and the mean total cost for NHL patients was Indonesian Rupiah (IDR) 5,178,146. The highest mean cost burden was on chemotherapy drugs with a value of IDR 6,333,315. Based on the regimen, the highest cost burden was R-CHOP-Bleo with a mean cost of IDR 8,764,091.

Conclusion: Based on the results, the highest cost burden for chemotherapy among JKN patients with NHL in Indonesia was attributed to R-CHOP-Bleo regimen with a mean of IDR 8,764,091.

查看原文本刊更多论文

印度尼西亚医疗保险和社会保险/Jaminan Kesehatan Nasional (JKN) 非霍奇金淋巴瘤患者化疗的成本负担。

背景：癌症是导致全球死亡的主要原因之一，给医疗保健部门造成了巨大的经济负担。在印度尼西亚的其他癌症类型中，非霍奇金淋巴瘤（NHL）的发病率排名第五。非霍奇金淋巴瘤患者的化疗费用由国家医疗保险和社会保障/Jaminan Kesehatan Nasional（JKN）的国家医疗保险计划提供：本研究旨在分析JKN NHL患者化疗的成本负担：2021年，在印度尼西亚东爪哇的一家医院对接受化疗的NHL患者进行了一项回顾性横断面观察研究。数据摘要：结果显示，就诊患者以女性为主（55%），年龄在31至40岁之间的患者占相当大的比例（32%），大多数患者是属于 "捐助补助金领取者/Penerima Bantuan Iuran (PBI) "类别的JKN参与者（64%）。化疗方案最多的是R-CHOP（68%），NHL患者的平均总费用为5,178,146印尼盾。化疗药物的平均费用负担最高，为 6,333,315 印尼盾。结论：根据治疗方案，R-CHOP-Bleo疗法的平均费用为8,764,091印尼盾，成本负担最高：根据研究结果，印尼JKN NHL患者化疗费用负担最高的是R-CHOP-Bleo方案，平均费用为8,764,091印尼盾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...